Cargando…

Cascade Screening and Treatment Initiation in Young Adults with Heterozygous Familial Hypercholesterolemia

Heterozygous familial hypercholesterolemia (HeFH) creates elevated low-density lipoprotein cholesterol (LDL-C), causing premature atherosclerotic cardiovascular disease (ASCVD). Guidelines recommend cascade screening relatives and starting statin therapy at 8–10 years old, but adherence to these rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peterson, Amy L., Bang, Matthew, Block, Robert C., Wong, Nathan D., Karalis, Dean G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306062/ https://www.ncbi.nlm.nih.gov/pubmed/34300259 http://dx.doi.org/10.3390/jcm10143090

Ejemplares similares

Long‐Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening
por: Kjærgaard, Kasper Aalbæk, et al.
Publicado: (2017)

Genetic screening for homozygous and heterozygous familial hypercholesterolemia
por: Izar, Maria C, et al.
Publicado: (2010)

Cascade Screening for Familial Hypercholesterolemia (FH)
por: Ned, Renée M., et al.
Publicado: (2011)

Estimated Yield of Screening for Heterozygous Familial Hypercholesterolemia With and Without Genetic Testing in US Adults
por: Bellows, Brandon K., et al.
Publicado: (2022)

Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
por: McGowan, Mary P., et al.
Publicado: (2019)

Stakeholder Views on Active Cascade Screening for Familial Hypercholesterolemia
por: van El, Carla G., et al.
Publicado: (2018)

Genetic variations in familial hypercholesterolemia and cascade screening in East Asians
por: Chan, Melody Lok‐Yi, et al.
Publicado: (2018)

CASCADE screening and registry of familial hypercholesterolemia in Iran: Rationale and design
por: Vaseghi, Golnaz, et al.
Publicado: (2019)

Predictors of Family Enrollment in a Genetic Cascade Screening Program for Familial Hypercholesterolemia
por: Silva, Pãmela Rodrigues de Souza, et al.
Publicado: (2018)

Predictors of Family Recruitment in a Program of Genetic Cascade Screening for Familial Hypercholesterolemia
por: Izar, Maria Cristina de Oliveira, et al.
Publicado: (2018)

Cascade Screening in Familial Hypercholesterolemia: Achieving Buy-In and Turning Patients Into Partners
por: Khoury, Michael
Publicado: (2023)

Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia
por: Ershova, Alexandra I., et al.
Publicado: (2016)

Phenotypic vs. genetic cascade screening for familial hypercholesterolemia: A case report
por: Blokhina, Anastasia V., et al.
Publicado: (2022)

Role of colesevelam in managing heterozygous familial hypercholesterolemia in adolescents and children
por: Sonnett, Travis, et al.
Publicado: (2010)

Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside
por: Agarwala, Anandita, et al.
Publicado: (2021)

Awareness and knowledge of heterozygous familial hypercholesterolemia among Serbian pediatricians
por: Bjelakovic, Ljiljana, et al.
Publicado: (2023)

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)
por: Sudano, Isabella, et al.
Publicado: (2022)

Genetic Spectrum and Cascade Screening of Familial Hypercholesterolemia in Routine Clinical Setting in Hong Kong
por: Yip, Man-Kwan, et al.
Publicado: (2023)

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
por: Ginsberg, Henry N., et al.
Publicado: (2019)

Aorta of young and middle-aged heterozygous familial hypercholesterolemia patients shows no functional or morphological impairment assessed by MRI
por: Soljanlahti, Sami, et al.
Publicado: (2008)

Developing and Optimizing Innovative Tools to Address Familial Hypercholesterolemia Underdiagnosis: Identification Methods, Patient Activation, and Cascade Testing for Familial Hypercholesterolemia
por: Campbell-Salome, Gemme, et al.
Publicado: (2021)

Recall by genotype and cascade screening for familial hypercholesterolemia in a population-based biobank from Estonia
por: Alver, Maris, et al.
Publicado: (2018)

Correlates of Coronary Artery Calcification Prevalence and Severity in Patients With Heterozygous Familial Hypercholesterolemia
por: Drouin-Chartier, Jean-Philippe, et al.
Publicado: (2020)

Cataract Surgery in Elderly Subjects with Heterozygous Familial Hypercholesterolemia in Prolonged Treatment with Statins
por: Marco-Benedí, Victoria, et al.
Publicado: (2021)

How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?
por: Kataoka, Yu, et al.
Publicado: (2022)

Recognition and Treatment of Homozygous Familial Hypercholesterolemia by Primary Care Physicians: a Survey from the National Lipid Association
por: Hemphill, Linda, et al.
Publicado: (2020)

Premature Coronary Artery Disease and Familial Hypercholesterolemia: Need for Early Diagnosis and Cascade Screening in the Indian Population
por: Setia, N., et al.
Publicado: (2012)

A proof-of-concept study of cascade screening for Familial Hypercholesterolemia in the US, adapted from the Dutch model
por: McGowan, Mary P., et al.
Publicado: (2021)

LDL apheresis in a woman with severe heterozygous familial hypercholesterolemia. Late, but not too late
por: Mickiewicz, Agnieszka, et al.
Publicado: (2015)

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives
por: Catapano, Alberico Luigi, et al.
Publicado: (2017)

Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters
por: Vuorio, Alpo, et al.
Publicado: (2018)

Myocardial strain impairment, heterozygous familial hypercholesterolemia and systemic arterial hypertension: Is there a link?
por: Vitarelli, Antonio
Publicado: (2021)

Burden of cardiovascular disease in a large contemporary cohort of patients with heterozygous familial hypercholesterolemia
por: Ferrières, Jean, et al.
Publicado: (2022)

Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients
por: Matta, Anthony, et al.
Publicado: (2023)

Successful Treatment of Homozygous Familial Hypercholesterolemia Using Cascade Filtration Plasmapheresis
por: Kardaş1, Fatih, et al.
Publicado: (2012)

Design of a Controlled Trial of Cascade Screening for Hypercholesterolemia: The (CASH) Study
por: Kullo, Iftikhar J., et al.
Publicado: (2018)

Prevalent Coronary Artery Disease and Undertreatment in Heterozygous Familial Hypercholesterolemia -Real-World Data and “Heterozygous FH Score” from FAME Study-
por: Nohara, Atsushi
Publicado: (2022)

Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia
por: Parhofer, Klaus G
Publicado: (2012)

An Eight-Week Trial Investigating the Efficacy and Tolerability of Atorvastatin for Children and Adolescents With Heterozygous Familial Hypercholesterolemia
por: Gandelman, Kuan, et al.
Publicado: (2011)

Heterozygous Familial Hypercholesterolemia With APOE Haplotype: A Prospective Harbinger of a Catastrophic Cardiovascular Event
por: Lasam, Glenmore, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_i3damsel8tnd2r0e9i7k49ckjf